サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1514227

降圧剤の世界市場

Anti-Hypertensive Drugs

出版日
ページ情報
英文 326 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.99円
降圧剤の世界市場
出版日: 2024年07月17日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 326 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

降圧剤の世界市場は2030年までに297億米ドルに到達

2023年に246億米ドルと推定される降圧剤の世界市場は、2023年から2030年にかけてCAGR 2.8%で成長し、2030年には297億米ドルに達すると予測されます。本レポートで分析したセグメントの1つであるカルシウム拮抗薬は、CAGR 3.2%を記録し、分析期間終了時には72億米ドルに達すると予想されます。ACE阻害剤セグメントの成長率は、分析期間中CAGR 3.7%と推定されます。

米国市場は67億米ドルと推定、中国はCAGR 4.7%で成長予測

米国の降圧剤市場は、2023年に67億米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに58億米ドルの市場規模に達すると予測され、分析期間2023-2030年のCAGRは4.7%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ1.5%と2.3%と予測されています。欧州では、ドイツがCAGR 1.9%で成長すると予測されています。

降圧剤の世界市場動向- 主要動向と促進要因のまとめ

降圧剤の世界市場は、製薬業界における主要セグメントであり、世界で約15億人が罹患している高血圧の蔓延が大きな原動力となっています。高血圧は世界的に最も一般的な慢性疾患の一つであるにもかかわらず、血圧のメカニズムや新しい治療法に関する革新的な研究は近年顕著に減少しています。特に低所得国で高血圧の負担が増加していることに加え、裕福な国では診断不足や治療不足が続いていることから、この減少は特に懸念されます。

高齢化、肥満率の増加、座りっぱなしのライフスタイル、塩分摂取量の多さなど食生活の乱れなどが背景にあり、降圧薬の需要は伸び続けています。これに対応するため、同市場では、治療レジメンを簡素化するために複数の薬剤を単一の剤形に配合した併用療法など、より優れた有効性、副作用の軽減、患者のコンプライアンス向上を実現する新薬療法の開拓へとシフトしています。さらに、ゲノミクスとバイオテクノロジーの進歩により、治療への個別化アプローチへの道が開かれつつあり、個々の患者の遺伝子プロファイルに合わせた投薬が可能となり、高血圧管理の有効性が高まっています。

新興国では、中産階級の拡大と医療保険制度の充実により、降圧治療へのアクセスが大幅に伸びています。このような拡大は、高血圧のリスクに関する国民の意識を高め、効果的な管理方法を促進することを目的とした、政府やヘルスケアによる取り組みによって支えられています。さらに、スマートフォンのアプリと連動したデジタル血圧モニターなど、在宅医療モニタリング技術の台頭は、患者が自分の状態をリアルタイムでモニタリングできるようにすることで、より良い患者関与と治療へのアドヒアランスを促進しています。しかし、製薬業界は厳しい規制環境や薬価引き下げ圧力などの課題にも直面しており、製薬会社は費用対効果の高い医薬品製造・流通方法の革新を迫られています。

調査対象企業の例（全143社）

  • Actelion Pharmaceuticals Ltd.
  • AstraZeneca PLC
  • Bayer AG
  • Boehringer Ingelheim GmbH
  • Daiichi Sankyo Co., Ltd.
  • Johnson & Johnson
  • Lupin Pharmaceuticals, Inc.
  • Merck & Co., Inc.
  • Novartis International AG
  • Pfizer, Inc.
  • Sanofi
  • Takeda Pharmaceutical Co., Ltd.

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP-6021

Global Anti-Hypertensive Drugs Market to Reach US$29.7 Billion by 2030

The global market for Anti-Hypertensive Drugs estimated at US$24.6 Billion in the year 2023, is expected to reach US$29.7 Billion by 2030, growing at a CAGR of 2.8% over the analysis period 2023-2030. Calcium Channel Blockers, one of the segments analyzed in the report, is expected to record a 3.2% CAGR and reach US$7.2 Billion by the end of the analysis period. Growth in the ACE Inhibitors segment is estimated at 3.7% CAGR over the analysis period.

The U.S. Market is Estimated at US$6.7 Billion While China is Forecast to Grow at 4.7% CAGR

The Anti-Hypertensive Drugs market in the U.S. is estimated at US$6.7 Billion in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$5.8 Billion by the year 2030 trailing a CAGR of 4.7% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.5% and 2.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.9% CAGR.

Global Anti-Hypertensive Drugs Market - Key Trends and Drivers Summarized

The global market for anti-hypertensive drugs is a major segment within the pharmaceutical industry, driven largely by the widespread prevalence of hypertension, which affects approximately 1.5 billion people worldwide. Despite hypertension being one of the most common chronic diseases globally, there has been a noticeable decline in innovative research on blood pressure mechanisms and new treatments in recent years. This decline is particularly concerning given the rising burden of the disease, especially in low-income countries, coupled with ongoing issues of underdiagnosis and undertreatment in wealthier nations.

The demand for anti-hypertensive medications continues to grow, fueled by an aging population, increasing rates of obesity, sedentary lifestyles, and poor dietary choices such as high salt intake. In response, the market is seeing a shift towards the development of new drug therapies that offer better efficacy, reduced side effects, and improved patient compliance, such as combination therapies that incorporate multiple drugs in a single dosage form to simplify treatment regimens. Furthermore, advancements in genomics and biotechnology are paving the way for more personalized approaches to treatment, allowing for medications to be tailored to the genetic profiles of individual patients, enhancing the effectiveness of hypertension management.

Emerging economies are witnessing significant growth in access to anti-hypertensive treatments, driven by expanding middle classes and better health insurance coverage. This expansion is supported by government and healthcare initiatives aimed at increasing public awareness about the risks of high blood pressure and promoting effective management practices. Additionally, the rise of home health monitoring technologies, such as digital blood pressure monitors linked to smartphone apps, is promoting better patient engagement and adherence to treatment by enabling patients to monitor their condition in real-time. However, the industry also faces challenges such as stringent regulatory environments and pressure to reduce drug prices, which are pushing pharmaceutical companies to innovate in cost-effective drug production and distribution methods.

Select Competitors (Total 143 Featured) -

  • Actelion Pharmaceuticals Ltd.
  • AstraZeneca PLC
  • Bayer AG
  • Boehringer Ingelheim GmbH
  • Daiichi Sankyo Co., Ltd.
  • Johnson & Johnson
  • Lupin Pharmaceuticals, Inc.
  • Merck & Co., Inc.
  • Novartis International AG
  • Pfizer, Inc.
  • Sanofi
  • Takeda Pharmaceutical Co., Ltd.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Anti-Hypertensive Drugs - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
    • Global Economic Update
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Increasing Prevalence of Hypertension Drives Anti-Hypertensive Drugs Market Growth
    • Technological Advancements in Drug Formulations Propel Market Innovation
    • Rising Adoption of Combination Therapies Expands Addressable Market Opportunity
    • Growth in Geriatric Population Strengthens Business Case for Anti-Hypertensive Drugs
    • Awareness, Early Screening & Focus on Hypertension Management Spur Market Growth
    • Integration of Telemedicine in Hypertension Care, a Key Trend Fueling Growth
    • Expansion of Pharmaceutical Industry in Emerging Markets Accelerates Market Growth
    • Increasing Use of Anti-Hypertensive Drugs in Diabetic Patients Sustains Market Growth
    • Rising Demand for Anti-Hypertensive Drugs in Obese Population. Here is the Story
    • Long-acting Anti-Hypertensive Drugs Grow in Popularity
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Recent Past, Current & Future Analysis for Anti-Hypertensive Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 2: World Historic Review for Anti-Hypertensive Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 3: World 16-Year Perspective for Anti-Hypertensive Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Diuretics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 5: World Historic Review for Diuretics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 6: World 16-Year Perspective for Diuretics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 7: World Recent Past, Current & Future Analysis for ACE Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 8: World Historic Review for ACE Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 9: World 16-Year Perspective for ACE Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Calcium Channel Blockers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 11: World Historic Review for Calcium Channel Blockers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 12: World 16-Year Perspective for Calcium Channel Blockers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 13: World Recent Past, Current & Future Analysis for Other Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 14: World Historic Review for Other Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 15: World 16-Year Perspective for Other Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 16: World Recent Past, Current & Future Analysis for Beta-Adrenergic Blocker by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 17: World Historic Review for Beta-Adrenergic Blocker by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 18: World 16-Year Perspective for Beta-Adrenergic Blocker by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 19: World Recent Past, Current & Future Analysis for Vasodilators by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 20: World Historic Review for Vasodilators by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 21: World 16-Year Perspective for Vasodilators by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 22: World Anti-Hypertensive Drugs Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Anti-Hypertensive Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 23: USA Recent Past, Current & Future Analysis for Anti-Hypertensive Drugs by Type - Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 24: USA Historic Review for Anti-Hypertensive Drugs by Type - Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 25: USA 16-Year Perspective for Anti-Hypertensive Drugs by Type - Percentage Breakdown of Value Sales for Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types for the Years 2014, 2024 & 2030
  • CANADA
    • TABLE 26: Canada Recent Past, Current & Future Analysis for Anti-Hypertensive Drugs by Type - Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 27: Canada Historic Review for Anti-Hypertensive Drugs by Type - Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 28: Canada 16-Year Perspective for Anti-Hypertensive Drugs by Type - Percentage Breakdown of Value Sales for Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types for the Years 2014, 2024 & 2030
  • JAPAN
    • Anti-Hypertensive Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 29: Japan Recent Past, Current & Future Analysis for Anti-Hypertensive Drugs by Type - Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 30: Japan Historic Review for Anti-Hypertensive Drugs by Type - Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 31: Japan 16-Year Perspective for Anti-Hypertensive Drugs by Type - Percentage Breakdown of Value Sales for Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types for the Years 2014, 2024 & 2030
  • CHINA
    • Anti-Hypertensive Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 32: China Recent Past, Current & Future Analysis for Anti-Hypertensive Drugs by Type - Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 33: China Historic Review for Anti-Hypertensive Drugs by Type - Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 34: China 16-Year Perspective for Anti-Hypertensive Drugs by Type - Percentage Breakdown of Value Sales for Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types for the Years 2014, 2024 & 2030
  • EUROPE
    • Anti-Hypertensive Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 35: Europe Recent Past, Current & Future Analysis for Anti-Hypertensive Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 36: Europe Historic Review for Anti-Hypertensive Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 37: Europe 16-Year Perspective for Anti-Hypertensive Drugs by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
    • TABLE 38: Europe Recent Past, Current & Future Analysis for Anti-Hypertensive Drugs by Type - Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 39: Europe Historic Review for Anti-Hypertensive Drugs by Type - Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 40: Europe 16-Year Perspective for Anti-Hypertensive Drugs by Type - Percentage Breakdown of Value Sales for Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types for the Years 2014, 2024 & 2030
  • FRANCE
    • Anti-Hypertensive Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 41: France Recent Past, Current & Future Analysis for Anti-Hypertensive Drugs by Type - Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 42: France Historic Review for Anti-Hypertensive Drugs by Type - Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 43: France 16-Year Perspective for Anti-Hypertensive Drugs by Type - Percentage Breakdown of Value Sales for Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types for the Years 2014, 2024 & 2030
  • GERMANY
    • Anti-Hypertensive Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 44: Germany Recent Past, Current & Future Analysis for Anti-Hypertensive Drugs by Type - Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 45: Germany Historic Review for Anti-Hypertensive Drugs by Type - Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 46: Germany 16-Year Perspective for Anti-Hypertensive Drugs by Type - Percentage Breakdown of Value Sales for Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types for the Years 2014, 2024 & 2030
  • ITALY
    • TABLE 47: Italy Recent Past, Current & Future Analysis for Anti-Hypertensive Drugs by Type - Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 48: Italy Historic Review for Anti-Hypertensive Drugs by Type - Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 49: Italy 16-Year Perspective for Anti-Hypertensive Drugs by Type - Percentage Breakdown of Value Sales for Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • Anti-Hypertensive Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 50: UK Recent Past, Current & Future Analysis for Anti-Hypertensive Drugs by Type - Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 51: UK Historic Review for Anti-Hypertensive Drugs by Type - Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 52: UK 16-Year Perspective for Anti-Hypertensive Drugs by Type - Percentage Breakdown of Value Sales for Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types for the Years 2014, 2024 & 2030
  • SPAIN
    • TABLE 53: Spain Recent Past, Current & Future Analysis for Anti-Hypertensive Drugs by Type - Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 54: Spain Historic Review for Anti-Hypertensive Drugs by Type - Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 55: Spain 16-Year Perspective for Anti-Hypertensive Drugs by Type - Percentage Breakdown of Value Sales for Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types for the Years 2014, 2024 & 2030
  • RUSSIA
    • TABLE 56: Russia Recent Past, Current & Future Analysis for Anti-Hypertensive Drugs by Type - Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 57: Russia Historic Review for Anti-Hypertensive Drugs by Type - Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 58: Russia 16-Year Perspective for Anti-Hypertensive Drugs by Type - Percentage Breakdown of Value Sales for Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 59: Rest of Europe Recent Past, Current & Future Analysis for Anti-Hypertensive Drugs by Type - Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 60: Rest of Europe Historic Review for Anti-Hypertensive Drugs by Type - Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 61: Rest of Europe 16-Year Perspective for Anti-Hypertensive Drugs by Type - Percentage Breakdown of Value Sales for Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • Anti-Hypertensive Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 62: Asia-Pacific Recent Past, Current & Future Analysis for Anti-Hypertensive Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 63: Asia-Pacific Historic Review for Anti-Hypertensive Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 64: Asia-Pacific 16-Year Perspective for Anti-Hypertensive Drugs by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
    • TABLE 65: Asia-Pacific Recent Past, Current & Future Analysis for Anti-Hypertensive Drugs by Type - Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 66: Asia-Pacific Historic Review for Anti-Hypertensive Drugs by Type - Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 67: Asia-Pacific 16-Year Perspective for Anti-Hypertensive Drugs by Type - Percentage Breakdown of Value Sales for Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types for the Years 2014, 2024 & 2030
  • AUSTRALIA
    • Anti-Hypertensive Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
    • TABLE 68: Australia Recent Past, Current & Future Analysis for Anti-Hypertensive Drugs by Type - Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 69: Australia Historic Review for Anti-Hypertensive Drugs by Type - Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 70: Australia 16-Year Perspective for Anti-Hypertensive Drugs by Type - Percentage Breakdown of Value Sales for Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types for the Years 2014, 2024 & 2030
  • INDIA
    • Anti-Hypertensive Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
    • TABLE 71: India Recent Past, Current & Future Analysis for Anti-Hypertensive Drugs by Type - Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 72: India Historic Review for Anti-Hypertensive Drugs by Type - Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 73: India 16-Year Perspective for Anti-Hypertensive Drugs by Type - Percentage Breakdown of Value Sales for Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types for the Years 2014, 2024 & 2030
  • SOUTH KOREA
    • TABLE 74: South Korea Recent Past, Current & Future Analysis for Anti-Hypertensive Drugs by Type - Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 75: South Korea Historic Review for Anti-Hypertensive Drugs by Type - Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 76: South Korea 16-Year Perspective for Anti-Hypertensive Drugs by Type - Percentage Breakdown of Value Sales for Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types for the Years 2014, 2024 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 77: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Anti-Hypertensive Drugs by Type - Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 78: Rest of Asia-Pacific Historic Review for Anti-Hypertensive Drugs by Type - Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 79: Rest of Asia-Pacific 16-Year Perspective for Anti-Hypertensive Drugs by Type - Percentage Breakdown of Value Sales for Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types for the Years 2014, 2024 & 2030
  • LATIN AMERICA
    • Anti-Hypertensive Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
    • TABLE 80: Latin America Recent Past, Current & Future Analysis for Anti-Hypertensive Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 81: Latin America Historic Review for Anti-Hypertensive Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 82: Latin America 16-Year Perspective for Anti-Hypertensive Drugs by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
    • TABLE 83: Latin America Recent Past, Current & Future Analysis for Anti-Hypertensive Drugs by Type - Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 84: Latin America Historic Review for Anti-Hypertensive Drugs by Type - Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 85: Latin America 16-Year Perspective for Anti-Hypertensive Drugs by Type - Percentage Breakdown of Value Sales for Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types for the Years 2014, 2024 & 2030
  • ARGENTINA
    • TABLE 86: Argentina Recent Past, Current & Future Analysis for Anti-Hypertensive Drugs by Type - Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 87: Argentina Historic Review for Anti-Hypertensive Drugs by Type - Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 88: Argentina 16-Year Perspective for Anti-Hypertensive Drugs by Type - Percentage Breakdown of Value Sales for Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types for the Years 2014, 2024 & 2030
  • BRAZIL
    • TABLE 89: Brazil Recent Past, Current & Future Analysis for Anti-Hypertensive Drugs by Type - Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 90: Brazil Historic Review for Anti-Hypertensive Drugs by Type - Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 91: Brazil 16-Year Perspective for Anti-Hypertensive Drugs by Type - Percentage Breakdown of Value Sales for Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types for the Years 2014, 2024 & 2030
  • MEXICO
    • TABLE 92: Mexico Recent Past, Current & Future Analysis for Anti-Hypertensive Drugs by Type - Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 93: Mexico Historic Review for Anti-Hypertensive Drugs by Type - Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 94: Mexico 16-Year Perspective for Anti-Hypertensive Drugs by Type - Percentage Breakdown of Value Sales for Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types for the Years 2014, 2024 & 2030
  • REST OF LATIN AMERICA
    • TABLE 95: Rest of Latin America Recent Past, Current & Future Analysis for Anti-Hypertensive Drugs by Type - Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 96: Rest of Latin America Historic Review for Anti-Hypertensive Drugs by Type - Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 97: Rest of Latin America 16-Year Perspective for Anti-Hypertensive Drugs by Type - Percentage Breakdown of Value Sales for Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types for the Years 2014, 2024 & 2030
  • MIDDLE EAST
    • Anti-Hypertensive Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
    • TABLE 98: Middle East Recent Past, Current & Future Analysis for Anti-Hypertensive Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 99: Middle East Historic Review for Anti-Hypertensive Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 100: Middle East 16-Year Perspective for Anti-Hypertensive Drugs by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
    • TABLE 101: Middle East Recent Past, Current & Future Analysis for Anti-Hypertensive Drugs by Type - Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 102: Middle East Historic Review for Anti-Hypertensive Drugs by Type - Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 103: Middle East 16-Year Perspective for Anti-Hypertensive Drugs by Type - Percentage Breakdown of Value Sales for Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types for the Years 2014, 2024 & 2030
  • IRAN
    • TABLE 104: Iran Recent Past, Current & Future Analysis for Anti-Hypertensive Drugs by Type - Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 105: Iran Historic Review for Anti-Hypertensive Drugs by Type - Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 106: Iran 16-Year Perspective for Anti-Hypertensive Drugs by Type - Percentage Breakdown of Value Sales for Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types for the Years 2014, 2024 & 2030
  • ISRAEL
    • TABLE 107: Israel Recent Past, Current & Future Analysis for Anti-Hypertensive Drugs by Type - Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 108: Israel Historic Review for Anti-Hypertensive Drugs by Type - Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 109: Israel 16-Year Perspective for Anti-Hypertensive Drugs by Type - Percentage Breakdown of Value Sales for Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types for the Years 2014, 2024 & 2030
  • SAUDI ARABIA
    • TABLE 110: Saudi Arabia Recent Past, Current & Future Analysis for Anti-Hypertensive Drugs by Type - Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 111: Saudi Arabia Historic Review for Anti-Hypertensive Drugs by Type - Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 112: Saudi Arabia 16-Year Perspective for Anti-Hypertensive Drugs by Type - Percentage Breakdown of Value Sales for Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types for the Years 2014, 2024 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 113: UAE Recent Past, Current & Future Analysis for Anti-Hypertensive Drugs by Type - Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 114: UAE Historic Review for Anti-Hypertensive Drugs by Type - Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 115: UAE 16-Year Perspective for Anti-Hypertensive Drugs by Type - Percentage Breakdown of Value Sales for Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types for the Years 2014, 2024 & 2030
  • REST OF MIDDLE EAST
    • TABLE 116: Rest of Middle East Recent Past, Current & Future Analysis for Anti-Hypertensive Drugs by Type - Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 117: Rest of Middle East Historic Review for Anti-Hypertensive Drugs by Type - Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 118: Rest of Middle East 16-Year Perspective for Anti-Hypertensive Drugs by Type - Percentage Breakdown of Value Sales for Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types for the Years 2014, 2024 & 2030
  • AFRICA
    • Anti-Hypertensive Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
    • TABLE 119: Africa Recent Past, Current & Future Analysis for Anti-Hypertensive Drugs by Type - Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 120: Africa Historic Review for Anti-Hypertensive Drugs by Type - Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 121: Africa 16-Year Perspective for Anti-Hypertensive Drugs by Type - Percentage Breakdown of Value Sales for Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types for the Years 2014, 2024 & 2030

IV. COMPETITION